Search Results
Your search for The ASCO Post matches 277 pages
Showing 51 - 100FDA Pipeline: Breakthrough Therapy for Melanoma, Investigational New Drug for Advanced Solid Tumors
This week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bempegaldesleukin in combination with nivolumab for advanced melanoma and cleared an investigational new drug application for a phase I trial of SB 11285 in advanced solid tumors. Breakthrough...
Survey Finds Majority of Americans Are Unfamiliar With Cutaneous Squamous Cell Carcinoma
Nearly-three quarters of Americans are not familiar with cutaneous squamous cell carcinoma, the second most common type of cancer in the United States, according to a new survey conducted by The Harris Poll on behalf of The Skin Cancer Foundation. Cutaneous squamous cell carcinoma is more common...
Family History of Melanoma May Increase Risk for Nonmelanoma Skin Cancers
A study by Wei et al in the Journal of the American Academy of Dermatology has found that individuals with a first-degree relative with a history of melanoma are at an increased risk for melanomas and keratinocyte cancers such as squamous cell carcinoma and basal cell carcinoma. Methods...
Upgrading of Nonmelanoma Skin Cancers at the Time of Mohs Surgery
Nonmelanoma skin cancers may display an aggressive histologic subtype that is not diagnosed on initial biopsy. In a prospective, cross-sectional study reported by Kyllo et al in the Journal of the American Academy of Dermatology, researchers determined that a significant portion of nomelanoma...
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
15-ICML: Final Data From ALCANZA: Brentuximab Vedotin for CD30-Positive CTCL
Final analyses from the ALCANZA study, a phase III trial investigating brentuximab vedotin vs physician’s choice for the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL), were presented by Horwitz et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract...
Performance of Machine-Learning Classifiers in the Diagnosis of Pigmented Skin Lesions
In a study conducted under the supervision of researchers from the MedUni Vienna, human experts competed against computer algorithms in diagnosing pigmented skin lesions. The algorithms achieved better results when diagnosing, but had decreased performance for out-of-distribution images. These...
2019 ASCO: OPTiM Study on T-VEC for Unresectable Melanoma
New research on the immunotherapy talimogene laherparepvec (T-VEC)—an injectable oncolytic virus—for patients with unresectable melanoma was presented by Milhem et al at the 2019 ASCO Annual Meeting (Abstract 9524). Researchers reported the ad hoc analysis of progression-free survival...
Ahmad A. Tarhini, MD, PhD, on High-Risk Melanoma: Adjuvant Ipilimumab vs High-Dose Interferon-α2b
Ahmad A. Tarhini, MD, PhD, of Emory University and Winship Cancer Institute, discusses phase III findings from the U.S. Intergroup E1609 trial, which showed survival benefits for patients with resected high-risk melanoma—for the first time in the history of melanoma adjuvant therapy (Abstract...
Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers
Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...
Does Intake of Dietary Fat Increase Risk of Skin Cancer?
Dietary intake of fat is associated with several types of cancer, but few studies have explored the link between fat intake and the risk of skin cancer. In a study published by Park et al in Cancer Epidemiology, Biomarkers & Prevention, researchers examined the relationship between fat intake...
FDA Pipeline: Designation in Uveal Melanoma, Application for MDS Side-Effect Management
Over the past week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for metastatic uveal melanoma and received a biologics application for an agent to control anemia. Fast Track Designation for Tebentafusp in Metastatic Uveal Melanoma The FDA granted...
Skin Cancer 2019: Recurrence and Staging of Cutaneous Squamous Cell Carcinoma After Mohs Surgery
Mohs surgery is known to have lower recurrence rate compared to conventional wide excision for removal of cutaneous squamous cell carcinomas. However, cutaneous squamous cell carcinoma does sometimes recur—even after Mohs surgery. In a Korean study by Roh et al presented at the World Congress ...
Skin Cancer 2019: Small Study of Electrochemotherapy for Basal Cell Carcinomas in the Head and Neck Region
Increasing evidence is emerging about the effectiveness of electrochemotherapy in the treatment of basal cell carcinomas in the head and neck region. A study presented by Kis et al at the World Congress on Advanced Treatments and Technologies in Skin Cancer (Skin Cancer 2019) (Poster Board 6) aimed ...
Skin Cancer 2019: Reflectance Confocal Microscopy Plus Optical Coherence Tomography in Diagnosing Suspicious Basal Cell Carcinoma Lesions
The increasing incidence and prevalence of nonmelanoma skin cancers has led to the search for new and more efficient diagnostic imaging and therapy guidance approaches. However, proper selection of therapy requires the precise delineation of skin cancer margins. To address this need, researchers...
AACR 2019: Entinostat Plus Pembrolizumab in Patients With Melanoma Previously Treated With Anti–PD-1 Therapy
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed clinical responses in patients with melanoma that had progressed on prior anti–PD-1 treatment, according to results from the phase...
Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice
Chrysalyne Schmults, MD, of Brigham and Women’s Hospital, discusses treatment strategies in these nonmelanoma skin cancers, including surgery, forthcoming staging systems, and ongoing trials combining adjuvant radiotherapy and immunotherapy.
Immunotherapy Directed Against Precancerous Skin Lesions May Prevent Squamous Cell Carcinoma
A treatment previously shown to treat the precancerous skin lesions called actinic keratosis now appears to also reduce the chance that these pretreated lesions will develop into squamous cell carcinoma. In a report published by Rosenberg et al in JCI Insight, researchers found that treatment with...
Incidence of Nonmelanoma Skin Cancer in Recipients of Multiple Kidney Transplants
The incidence of nonmelanoma skin cancer may be more common in recipients of kidney transplants vs patients on maintenance dialysis. Researchers looked to determine if the risk of nonmelanoma skin cancer is lower during periods of graft loss with a return to dialysis vs during periods of...
New Patient Resource: NCCN Guidelines for Patients With Squamous Cell Skin Cancer
The National Comprehensive Cancer Network® (NCCN) has published a new book of patient information that explains prevention, diagnosis, and treatment for squamous cell skin cancer. Squamous cell and basal cell skin cancers are responsible for about 5 million annual incidents of nonmelanoma...
Is the Presence of Nevi on Extremities a Risk Factor for Melanoma and Nonmelanoma Skin Cancers?
The presence of nevi is an established risk factor for melanoma. In light of this, researchers examined the association between the presence of nevi on extremities and the risk of melanoma and nonmelanoma skin cancers. Their findings were published by Wei et al in the Journal of the American...
A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma
A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be...
2019 AAD: Disadvantages and Potential Improvements of Artificial Intelligence in Skin Cancer Detection
While artificial intelligence (AI) systems for skin cancer detection have shown promise in research settings, there is still a lot of work to be done before the technology is appropriate for real-world use. This was the topic of a scientific session at the 2019 American Academy of Dermatology (AAD) ...
AACR 2019: Diet May Influence Gut Microbiome and Response to Immunotherapy
Among patients with melanoma treated with anti–programmed cell death protein 1 (PD-1) immunotherapy, consumption of a high-fiber diet was associated with higher gut microbiome diversity and better response to treatment, according to data presented by Spencer et al at a presscast in advance of ...
Cutaneous T-Cell Lymphoma: Can Genetic Polymorphisms Help Select Patients for Treatment With Bexarotene?
Bexarotene is a retinoid approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have not responded to at least one previous treatment regimen. Hypertrigylceridemia is the most frequent adverse event related to treatment with bexarotene in CTCL. Even with prophylactic...
FDA Approves Adjuvant Pembrolizumab for Melanoma
On February 15, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with melanoma with lymph node involvement following complete resection. Approval was based on the phase III EORTC1325/KEYNOTE-054 trial, a randomized, double-blind,...
Real-World Treatment Impact of Newer Agents on Survival of Patients With Metastatic Melanoma
The approval of several new agents for metastatic melanoma in the past several years has led to changes in how the disease is treated and managed. Treatments such as the programmed cell death protein 1 (PD-1) inhibitors pembrolizumab, ipilimumab, and nivolumab; BRAF inhibitors; and MEK inhibitors...
HLA Mismatch and Skin Cancer Risk After Organ Transplant
Data on the risk factors for the development of skin cancer after a solid organ transplant are limited. In a retrospective cohort study, researchers sought to determine the relationship between human leukocyte antigen (HLA) mismatch and risk of skin cancer after transplant. Their findings were...
How Effective Is Talimogene Laherparepvec Injection in Metastatic Melanoma?
Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40% of patients with tumors that could not be surgically removed, according to findings published by Louie et al in the Journal of the American...
FDA Pipeline: Updates on Treatments in NSCLC and Lymphomas, Plus New Dosimetry Software
The U.S. Food and Drug Administration (FDA) recently granted the following application, designations, and clearance: sBLA for Atezolizumab Plus Chemotherapy for First-Line Treatment of Metastatic, Nonsquamous NSCLC On January 17, the FDA accepted a supplemental biologics license application...
Surgical Factors Contributing to Invasive Squamous Cell Carcinoma Recurrence
Invasive squamous cell carcinoma (SCC) is typically treated surgically, with guidelines in place recommending surgical margins for excision based on the SCC being classified as low or high risk. Researchers undertook a study to examine recurrence rates of SCC after surgical excision, taking into...
Association Between Sun Exposure and BMI in the Development of Nonmelanoma Skin Cancer
Exposure to the sun, whether cumulative or intermittent, is a known risk factor for the development of nonmelanoma skin cancer (NMSC). Past studies have found that greater body mass index (BMI) actually lessens the risk of women developing NMSCs. With this in mind, researchers sought to determine...
Pilot Study of Intratumoral G100 in Merkel Cell Carcinoma
Multiple recent reports have addressed the activity of programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab and avelumab, in Merkel cell carcinoma. However, approximately half of all patients who receive these agents do not maintain a persistent response. In an...
ESMO Immuno-Oncology 2018: OpACIN Trial: Neoadjuvant Ipilimumab Plus Nivolumab in Stage III Melanoma
Updated data of the OpACIN study, which studied combined ipilimumab (Yervoy) plus nivolumab (Opdivo) administered as neoadjuvant or adjuvant therapy in patients with high-risk stage III melanoma, demonstrated high response rates upon neoadjuvant therapy and promising long-term clinical outcome,...
FDA Approves Pembrolizumab for Merkel Cell Carcinoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. The FDA’s approval was based on Cancer Immunotherapy Trials Network protocol 9...
ESMO Immuno-Oncology 2018: Does Proton Pump Inhibitor Therapy Impact the Efficacy of Nivolumab Plus Ipilimumab?
Patients with melanoma receiving proton pump inhibitors for comorbidities derived approximately half the clinical benefit from immunotherapy consisting of nivolumab (Opdivo) plus ipilimumab (Yervoy) as patients receiving the same combination but not treated with proton pump inhibitors, according to ...
Aggressive Squamous Cell Carcinoma in Solid Organ Transplant Recipients
Squamous cell carcinoma (SCC) is the most frequently diagnosed cancer in recipients of a solid organ transplant. When organ transplant recipients are diagnosed with SCC, they are also at higher risk for a more aggressive disease course, metastasis, and death than the general population. Researchers ...
Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (Abstract 1001).
Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England
Changes to the National Cancer Registration and Analysis Service (NCRAS) in England have allowed more accurate data analysis of primary and metastatic cutaneous squamous cell carcinoma (SCC) since 2013. Developed by experts at Queen Mary University of London and Public Health England, and...
NCRI 2018: Mortality in Men With Malignant Melanoma
The rate of men dying from malignant melanoma has risen in populations around the world, whereas in some countries, mortality rates for the disease are steady or falling for women, according to research presented by Yang et al at the 2018 National Cancer Research Institute (NCRI) Cancer Conference...
Meta-Analysis of Voriconazole Exposure and Risk of Cutaneous SCC
Voriconazole is an antifungal medication that is sometimes used to treat fungal infection in immunocompromised patients, including patients undergoing various transplants. In order to better assess the risk associated with voriconazole use after lung or hematopoietic stem cell transplant and...
Combining Genetic and Sun Exposure Data May Improve Prediction of Skin Cancer Risk
By combining data on individuals’ lifetime sun exposure and their genetics, researchers may be able to generate improved predictions of their risk of skin cancer, according to findings presented by Fontanillas et al at the 2018 American Society of Human Genetics Annual Meeting (Abstract PgmNr ...
Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.
Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.For more information about this ongoing trial, visit...
Jeffrey S. Weber, MD, PhD, on Discontinuing Immunotherapy: When Is the Right Time?
Jeffrey S. Weber, MD, PhD, of the NYU Langone Perlmutter Cancer Center, discusses how long people with melanoma should be treated with PD-1 blockade and the data on remission rates.
Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy
Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard ...
Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities
Paolo A. Ascierto, MD, of Istituto Nazionale Tumori–Fondazione Pascale, discusses the breakthroughs in melanoma treatment and the challenges of managing toxicities, especially endocrine and neurologic side effects, which can require lifetime hormone replacement and may cause permanent dysfunction.
Small Study of Neoadjuvant Combination Checkpoint Blockade in High-Risk Stage III Melanoma
Neoadjuvant combination checkpoint blockade showed activity among patients with high-risk stage III melanoma in a small study. However, a high incidence of side effects caused the trial to be closed early. These results were published by Amaria et al in Nature Medicine. The phase II...
Results From ECHELON-2: Brentuximab Vedotin in CD30-Expressing Peripheral T-Cell Lymphoma
The phase III ECHELON-2 clinical trial has met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) with brentuximab vedotin (Adcetris) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide,...
FDA Approves Cemiplimab-rwlc for Metastatic Cutaneous Squamous Cell Carcinoma
On September 28, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (SCC) or locally advanced cutaneous SCC who are not candidates for curative surgery or...
